


# ASTALIFE®

16 mg Astaksantin | 500 mg DHA



## Poor Ovarian Responder İçin Kanıtlanmış Destek



FDA ve GMP Sertifikalı üretim tesislerinde üretilmektedir.

[www.astalife.com.tr](http://www.astalife.com.tr)

# ASTALIFE ile Poor Overian

Astaksantin;  
POR hastalarında oksidatif stresi, inflamasyon ve apoptozu azaltarak, ART sonuçlarını iyileştirir.

Toplam Oosit sayısında anlamlı artış, (P=0,003)

MII oosit sayısında anlamlı artış, (P=0,004)

Dondurulmuş embriyo sayısında anlamlı artış, (P=0,037)

Yüksek kaliteli embriyo sayısında anlamlı artış, (P=0,014)

Oksidatif stres, inflamasyon ve apoptozun azaltılması, daha kaliteli oositlerin ve embriyoların gelişmesine yol açabilmektedir.

# Responder İçin Kanıtlanmış Destek

## Çalışma Amacı:

Astaksantin'in , POR hastalarında over yanıtı ve ART sonuçlarına etkisinin değerlendirilmesi.

## Çalışma Yöntemi:

### TASARIMI :

Üçlü-kör, randomize, plasebo kontrollü klinik çalışma

### HASTA PROFİLİ:

ICSI Uygulanan 60 infertil POR Hastası (POSEIDON Grup4), Yaş >35

Zayıf over rezervi (AMH <1,2ng/ml veya Antral Folikül Sayısı<5)Zayıf over rezervi (AMH <1,2ng/ml veya Antral Folikül Sayısı<5)

### UYGULAMA:

Astaksantin Grubu 12 mg oral /Gün, Kontrol grubu: Plasebo oral /Gün 8 hafta

Her iki gruba "GnRH antagonisti" protokolüyle kontrollü over stimülasyonu (COS) uygulandı

## Değerlendirilen Biyobelirteçler

OKSİDATİF STRES GÖSTERGELERİ : Serumda, Total Antioksidan Kapasite, Süperoksit Dismutaz, Malondialdehit, Foliküler sıvıda OS aynı parametreleri

İNFLAMASYON BELİRTEÇLERİ: IL 6, IL 8, VEGF (hem serum hem FF)

APOPTOZ BELİRTECİ: Hücresiz DNA [cfDNA] Analizi (ALU Kantitatif Polimeraz Zincir Reaksiyonu Yöntemi)

## Başlıca Bulgular

### 1-Serum antioksidan düzeyleri:

- o TAC belirgin şekilde arttı ( $p=0.030$ )
- o MDA önemli oranda azaldı ( $p=0.005$ )
- o SOD artışı da anlamlıydı ( $p=0.027$ )

### 2-İnflamasyon belirteçleri (serum & FF):

- o Serum IL 6 ( $p<0.001$ ), IL 8 ( $p=0.001$ ) ve VEGF ( $p=0.002$ ) anlamlı düşüş
- o Foliküler sıvıda IL 6, IL 8, VEGF ve cfDNA anlamlı azaldı (cfDNA  $p<0.001$ )

### 3-Üreme sonuçları:

- o Toplanan oosit sayısı anlamlı arttı ( $p=0.003$ )
- o MII (metafaz II) olgun oosit sayısı yükseldi ( $p=0.004$ )
- o Dondurulan embriyolar ( $p=0.037$ ) ve kaliteli embriyo sayısı ( $p=0.014$ ) da artış gösterdi

# ASTALIFE®

16 mg Astaksantin | 500 mg DHA

Yeni Bir Yaşam İçin...



ASTALIFE bileşimindeki DHA ağır metal ve Dioxin içermez...

#### Astalife Balık Yağı İçeren Takviye Edici Gıda

İçindekiler: Balık Yağı, Yumuşak Kapsül Bileşenleri (Sığır Jelatini, Su, Nem Verici: Gliserol).

Besin Öğeleri;

BİLEŞEN ADI	1 KAPSÜL İÇERİSİNDEKİ MİKTARI
Balık Yağı, *EPA (eikosapentaenoik asit) *DHA (dokosaheksaenoik asit)	1000 mg *100 mg (EPA) *500 mg (DHA)

#### Astalife Balık Yağı İçeren Takviye Edici Gıda

İçindekiler: Haematococcus Pluvialis Ekstresi (Astaksantin), Hacim Arttırıcı (Mikrokristalin Selüloz), Jelatin Kapsül (Sığır Jelatini), Topaklanmayı Önleyici (Yağ Asitlerinin Magnezyum Tuzları).

Besin Öğeleri;

BİLEŞEN ADI	1 KAPSÜL İÇERİSİNDEKİ MİKTARI
Haematococcus Pluvialis Ekstresi *Astaksantin	160 mg *16 mg

Gıda İşletmecisi: Done Med Danışmanlık Organizasyon Eğitim Sağlık Hizmetleri ve Tic. Ltd. Şti.

Bağlarbaşı Mah. Bağdat Cad. No: 457/102 Maltepe/İstanbul

Takviye Edici Gıda Onay Numarası: 003646-18.12.2017

Menşee; Türkiye (Bu gıda ithal bileşenlerden Türkiye'de üretilmiştir.)

Takviye edici gıdalar normal beslenmenin yerine geçemez.

Tavsiye Edilen Günlük Alım Dozu: Akşam yemeği sonrasında her iki kapsülün birlikte bir miktar suyla alınması önerilir.

Tavsiye edilen günlük porsiyonu aşmayınız.

Kullanıcı Grubu: Yetişkinlerin kullanımına uygundur.

Hamilelik ve emzirme dönemi ile hastalık veya ilaç kullanılması durumlarında doktorunuza danışın.

Tavsiye Edilen Tüketim Tarihi (TETT) Parti No ambalajın üzerinde yer almaktadır.

Muhafaza Koşulları: Çocukların ulaşamayacağı yerde saklayınız. Ambalajı içerisinde, kuru ve serin yerde muhafaza ediniz.

İLAÇ DEĞİLDİR

Hastalıkların önlenmesi veya tedavi edilmesi amacıyla kullanılmaz.

[www.astalife.com.tr](http://www.astalife.com.tr)



RESEARCH

Open Access



# Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: a randomized clinical trial

Anahid Shafie<sup>1</sup>, Ashraf Aleyasin<sup>2,3</sup>, Mojtaba Saffari<sup>4</sup>, Mojtaba Saedi<sup>1</sup>, Sahar Rostami<sup>1,5</sup>, Saeede Rezayi<sup>1</sup>, Seyed Danial Mohammadi<sup>1</sup> and Fardin Amidi<sup>1,5\*</sup>

## Abstract

**Background** Poor ovarian response (POR) to controlled ovarian stimulation (COS) remains challenging, especially in advanced-age women with diminished ovarian reserve, resulting in low live birth rates. Many patients prefer to conceive with their eggs, underscoring the need for improved treatments. This study explores astaxanthin potential as a COS adjuvant to improve ovarian response and assisted reproductive technology (ART) outcomes, considering its impact on oxidative stress (OS), inflammation, and apoptosis, which are key factors in POR.

**Methods** In this randomized, triple-blind, placebo-controlled trial, 60 infertile POR patients from POSEIDON Group 4 (the poorest prognosis category, age > 35 and poor ovarian reserve (anti-müllerian hormone < 1.2 ng/ml or antral follicle count < 5) undergoing intracytoplasmic sperm injection were enrolled. Patients were assigned to receive either 12 mg/day AST or placebo for eight weeks. All patients underwent a gonadotropin-releasing hormone antagonist regimen for COS. ART outcomes were compared between groups. Blood serum and follicular fluid (FF) were analyzed for OS markers (superoxide dismutase [SOD], total antioxidant capacity [TAC], and malondialdehyde [MDA]), and pro-inflammatory cytokines (interleukin-6 [IL-6], interleukin-8 [IL-8], and vascular endothelial growth factor [VEGF]) via enzyme-linked immunosorbent assay kits, and cell-free DNA [cfDNA] (apoptotic marker) via ALU quantitative polymerase chain reaction.

**Results** After the intervention, the AST group exhibited a significant elevation in serum ( $P=0.013$ ) and TAC ( $P=0.030$ ), accompanied by a significant reduction in serum MDA ( $P=0.005$ ). No significant differences between AST and placebo groups were observed in OS markers in FF. AST group showed significant reductions in the serum IL-6 ( $P<0.001$ ), IL-8 ( $P=0.001$ ), and VEGF ( $P=0.002$ ) levels following AST therapy. In the AST group, FF levels of IL-6 ( $P=0.001$ ), IL-8 ( $P=0.036$ ), VEGF ( $P=0.006$ ), and cfDNA ( $P<0.001$ ) were significantly lower than in the placebo group. Between-group comparisons showed significant differences in the alterations of serum SOD ( $P=0.027$ ), IL-6 ( $P<0.001$ ), and IL-8 ( $P=0.035$ ) levels between AST and placebo groups. The AST group showed significant increases in the number of retrieved oocytes ( $P=0.003$ ), MII oocytes ( $P=0.004$ ), frozen embryos ( $P=0.037$ ), and high-quality embryos ( $P=0.014$ ) compared to the placebo group.

\*Correspondence:

Fardin Amidi  
famidi@tums.ac.ir

Full list of author information is available at the end of the article




© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

**Conclusion** AST shows promise as a COS adjuvant therapy, potentially enhancing some ART outcomes in POR through alleviating OS, inflammation, and apoptosis.

**Trial registration** Clinical trial registration number: IRCT20230223057510N1, URL: <https://irct.behdasht.gov.ir/trial/68870>, registration date: 2023 March 16.

**Keywords** Poor ovarian response, Diminished ovarian reserve, Astaxanthin, Oxidative stress, Inflammation, Cell-free DNA, ART outcomes

### Graphical Abstract



### Introduction

Poor ovarian response (POR) poses a significant dilemma in the treatment of female infertility [1]. Its prevalence, estimated to be between 9% and 24%, is on the rise [2]. The success of assisted reproductive technology (ART) depends on the quantity of retrieved oocytes, and an optimal response involves developing 15 follicles [3, 4]. However, inadequate gonadotropin response during controlled ovarian stimulation (COS) results in poorer ART outcomes compared to normal ovarian responders [5]. According to the POSEIDON stratification, POR is characterized not only by a low number of retrieved oocytes but also by accounting for patient age, ovarian reserve markers (anti-müllerian hormone (AMH) or antral follicle count (AFC)), and previous ovarian response to stimulation. This classification aims to identify patients at risk of poor response better and personalize treatment strategies [6].

Approximately one-third of patients with diminished ovarian reserve (DOR) encounter a poor response to COS [7]. Despite extensive research, POR's precise pathophysiological mechanisms remain elusive. Studies suggest factors such as oxidative stress (OS), inflammation, and follicular atresia/apoptosis as potential contributors to its pathogenesis [8–11]. To begin with, emerging evidence highlights the role of OS-induced ovarian aging in the development of POR. Notably, POR serves as an early indicator of this aging process. OS can result in damage to vital intracellular macromolecules such as proteins, lipids, and DNA [12]. Additionally, disruption of pro-inflammatory cytokines and growth factors can adversely affect the interaction between FSH (Follicle-stimulating hormone) and its receptor (Follicle-stimulating hormone receptor (FSHR)), resulting in impaired proliferation and differentiation of granulosa cells (GCs) [9], crucial for oocyte development, ovulation, fertilization, and ROS

accumulation [13]. Lastly, elevated ROS levels damage cellular components and trigger cell death processes like apoptosis. Proper apoptosis regulation is vital for cellular homeostasis [14]. Ovarian cell apoptosis plays a vital role in the occurrence of extensive follicular atresia or regression, serving as a key mechanism in the process of ovarian aging. Oocyte apoptosis causes germ cell loss, while GCs apoptosis results in nutrient deprivation and metabolic disorders within the ovarian microenvironment [15]. Both contribute to declining ovarian function, with higher GC apoptosis observed in POR patients [16]. Cell-free DNA (cfDNA) refers to fragments of DNA that are derived from cellular apoptosis or necrosis and can be detected in various bodily fluids [17], including follicular fluid (FF) [18]. Increased cfDNA level serve as valuable non-invasive biomarker for early detection and prognosis in cancers and severe diseases [19]. The level of cfDNA in FF serves as an indicator of the proportion of apoptotic and necrotic cells within ovarian follicles [18]. Given that the composition of FF plays a crucial role in oocyte development and the quality of subsequent embryos, heightened levels of cfDNA in FF can have detrimental effects on the development of oocytes and embryos, potentially resulting in unsuccessful ART outcomes [20]. Women with poor ovarian reserve exhibit high concentrations of cfDNA in FF [21], which is attributed to the accelerated apoptosis in the ovary [22]. In light of the discussed content, the quantification of cfDNA in FF presents a non-invasive means to evaluate the quality of the follicular microenvironment.

In spite of various attempted stimulation protocols and treatments for POR, significant improvements in ART outcomes have been elusive [23]. Live birth rates (LBR) for POR patients remain below 10%. While egg donation yields better outcomes, a significant majority of POR patients still desire to conceive using their own eggs. This persistence in seeking conception with their own eggs, despite the limited success of certain treatment methods [23, 24] and the complex and time-sensitive nature of their condition [1], highlights the urgent need for a more effective and tailored solution for POR patients.

POR to COS drugs remains a challenge in infertility treatment, especially in advanced age and diminished ovarian reserve women. Recent interest in adjuvant treatment strategies for POR has grown [25–27]. Astaxanthin [3,3'-dihydroxy- $\beta$ ,  $\beta'$ -carotene-4,4'-dione, (AST)], a xanthophyll carotenoid known as the “king of antioxidants,” offers promise due to its multifaceted benefits [28, 29]. It has shown exceptional efficacy, surpassing Coenzyme Q10 (CoQ10), Alpha-Lipoic Acid, and vitamin C [30]. Studies highlight its antioxidant, anti-inflammatory, and anti-apoptotic properties [29]. AST activates the Nrf2/HO-1 pathway, enhancing antioxidant enzymes [31]. Because of its unique structure, ATX quenches singlet

oxygen, scavenges free radicals, and inhibits lipid peroxidation, safeguarding membranes [32]. It reduces pro-inflammatory cytokines via NF- $\kappa$ B and MAPK pathways [33]. Recent findings suggest AST's interplay between Nrf2 and NF- $\kappa$ B pathways, where Nrf2 activation antagonizes NF- $\kappa$ B, potentially leading to anti-inflammatory responses [34]. It also lessens apoptosis through ERK, NF- $\kappa$ B, and PI3K/Akt pathways [35, 36].

This study aims to investigate astaxanthin's therapeutic potential as a COS adjuvant on ovarian response and assisted reproductive technology (ART) outcomes. Additionally, we will assess astaxanthin's impact on OS, inflammation, and apoptotic markers.

## Methods

### Trial design

This clinical trial was a prospective, parallel, randomized, triple-blind, and placebo-controlled study. The trial recruited 60 infertile patients with POR undergoing ART at Omid Fertility Clinic in Tehran, Iran, between April and August 2023. Using POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) criteria, the investigation defined POR. The POSEIDON criteria subdivide poor responders into four groups, offering a more detailed and personalized classification of POR by considering age, ovarian reserve markers (Anti-müllerian hormone (AMH) and Antral follicle count (AFC)), and previous response to stimulation. In contrast, the Bologna criteria provide a broader and less specific classification. This approach allows for tailored treatment plans. We included only POSEIDON Group 4 patients in our study because this group represents the poorest prognosis category. By focusing on this subgroup, we aimed to investigate the potential benefits of our intervention in the most challenging cases, where improvement in outcomes would be most clinically significant. The inclusion criteria were: age > 35 years, and poor ovarian reserve (anti-müllerian hormone (AMH) < 1.2 ng/ml, or antral follicle count (AFC) < 5) (indicating low prognosis group 4 following the POSEIDON stratification) [6]. We excluded participants who had ovarian surgery or chemotherapy, endocrine disorders (such as diabetes, thyroid disease, polycystic ovary syndrome (PCOS), hyperprolactinemia), autoimmune disorders (such as the presence of anti-thyroid antibodies), endometriosis, recurrent spontaneous abortion, chromosomal abnormalities, uterine cavity abnormalities, tubal disorders, pelvic inflammatory disease, chronic infectious diseases, cancer, undergone more than three previous ART cycles, received hormone treatment or used intrauterine devices in the past three months, received treatment with dietary supplements and vitamins in the last three months, concurrent severe male

factor infertility (notably non-obstructive azoospermia), or spontaneous pregnancy during the intervention. The analysis enrolled POR patients with regular menstrual cycles.

**Ethical approval**

This study was performed in accordance with the principles of the Declaration of Helsinki. The trial received approval from the Deputy of the Research and Ethics Committee of TUMS (approval date: 2023 January 01; code: IR.TUMS.MEDICINE.REC.1401.636). Moreover, the protocol was recorded in the Iranian Registry of Clinical Trials (approval date: 2023 March 16; code: IRCT20230223057510N1). Before participating in the study, all participants provided written informed consent.


**Randomization and blinding**

To ensure unbiased treatment allocation, an independent statistician randomly assigned eligible patients to the AST ( $n=30$ ) or placebo ( $n=30$ ) groups in a 1:1 ratio by implementing the balanced block randomization design with a block size of 4. The randomization list was concealed using sequentially numbered, opaque envelopes. This triple-blind trial ensured that patients, researchers, embryologists, laboratory staff, and statisticians were unaware of the individual treatment allocation. It should be emphasized that the AST capsules were indistinguishable from the placebo capsules in size, shape, color, taste, and packaging. In addition, an independent party coded the medicinal content of each bottle with a code unknown to the research team. Also, outcome assessments were conducted by assessors who were completely unaware of participant group assignments. Figure 1

depicts patient flow across the trial in the Consolidated Standards of Reporting Trials (CONSORT) diagram.

**Trial procedures**

Infertile patients with POR undergoing intracytoplasmic sperm injection (ICSI) at Omid Fertility Clinic were enrolled if they met the inclusion criteria, which were evaluated by a gynecologist. All patients followed the standard ovarian stimulation with gonadotropin-releasing hormone (GnRH) antagonist. The AST group received 12 mg of oral AST capsules per day ( $3 \times 4$  mg capsules; AstaZine®, BGG Europe SA., Italy) until the ovum pick-up (OPU) day for eight weeks, while the placebo group received three capsules containing edible paraffin. The intervention duration and dosage were based on an earlier study [37]. Prior studies indicate that consuming 2 to 24 mg of AST daily for at least three weeks offers antioxidant benefits without safety issues or adverse effects [38, 39]. Given the limited number of clinical studies investigating the effects of AST on female infertility and reproductive outcomes [40], our study is innovative, as no clinical trials have specifically explored AST's effects on POR patients. Additionally, previous research has demonstrated that AST administration improves ART outcomes by increasing the number of mature (MII) oocytes retrieved [41–43]. The dosage and duration of the intervention were based on a previous randomized clinical trial, in which 12 mg/day of AST was administered for 60 days to women with PCOS. That study showed that AST enhances ART outcomes by elevating TAC levels in FF and modulating endoplasmic reticulum (ER) stress in GCs, without negatively affecting MDA or SOD levels, or compromising follicular health [37]. Furthermore, AST intake at this dosage improved



**Fig. 1** Patient flow across the trial



serum and FF apoptotic factor levels while modulating the expression of genes and proteins involved in the apoptosis pathway in GCs [44]. These studies also reported no adverse effects on follicular health, confirming that this dosage is safe and appropriate for our investigation. The absence of adverse effects on follicular health further underscores the suitability of this dosage, which we selected based on these promising findings. To monitor medication adherence and potential side effects, patients received weekly calls and monthly visits. Patients were advised to continue with their usual daily routines and to abstain from consuming any dietary supplements. The adherence rate was assessed via returned capsules on OPU day [45].

### Blood and FF collection

Following a prior study [41], 10 ml of venous blood was collected pre- and post-intervention (day of OPU) to assess OS markers and pro-inflammatory cytokines. Serum obtained by centrifugation (1500 g, 10 min) was stored at -80 °C for analysis. To reduce the risk of blood contamination, FF was only collected from the first follicle during the OPU. After centrifugation (3000 g for 15 min), the FF supernatants were filtered using 0.45 µm filters to remove cell debris and stored at -80 °C for later analysis [46]. Pre-intervention serum samples were collected on days 2 or 3 of the follicular phase. Post-intervention serum samples and FF were obtained on the day of OPU, with all samples collected under fasting conditions.

### OS markers and pro-inflammatory cytokines

Serum (pre- and post-intervention) and FF samples were analyzed for OS markers (superoxide dismutase [SOD], total antioxidant capacity [TAC], and malondialdehyde [MDA]) using human enzyme-linked immunosorbent assay (ELISA) kits (Zellbio, GmbH, Germany), and for pro-inflammatory cytokines (interleukin-6 [IL-6], interleukin-8 [IL-8], and vascular endothelial growth factor [VEGF]) using human ELISA kits (Karmania Pars Gene Co.; KPG, Iran). All parameters were blindly measured twice.

### CfDNA

Interestingly, measuring cfDNA levels—derived from apoptosis or necrosis—in FF has become a valuable diagnostic tool for assessing ovarian function [18, 19]. In poor ovarian reserve, higher cfDNA in FF is tied to accelerated ovarian apoptosis [47], adversely affecting ART outcomes [46]. CfDNA was extracted from FF using a previously described method [18, 48]. Quantification of total cfDNA utilized qPCR with ALU 115 primers. Each ALU-qPCR reaction included 1 µL of FF, 0.25 µM forward and reverse ALU 115 primers, and 5 µL of 2X SYBR Green I master mix (Amplicon, Denmark). CfDNA levels in FF were

measured via a standard curve derived from successive genomic DNA dilutions [48]. Negative controls (no template) were included, and each FF was tested in quadruplicate. To assess the origin of cfDNA, qPCR with ALU 247 primers was employed to quantify necrosis-related fragments. The Q247/Q115 ratio, indicating the proportion of cfDNA generated from necrosis over total cfDNA, was used to calculate cfDNA integrity [46]. If the cfDNA integrity falls below 0.5, it is primarily associated with apoptotic events; otherwise, it is predominantly linked to necrotic events. This study employed the following primers: ALU115 forward (5'-CCTGAGGTCAGGAGTTCCG AG-3'), ALU115 reverse (5'-CCCGAGTAGCTGGGATTACA-3'), ALU247 forward (5'-GTGGCTCACGCC TGTAATC-3'), and ALU247 reverse (5'-CAGGCTGGA GTGCAGTGG-3').

### COS protocol

At Omid Fertility Clinic in Tehran, Iran, the combination of a GnRH antagonist protocol and whole embryo freezing has proven to be the most effective method for inducing ovulation in POR patients. On day 2 of the menstrual cycle, a combination of recombinant FSH (rFSH) (225 IU/day, Gonal-F®, Merck Serono SA, Switzerland) and human menopausal gonadotrophin (HMG) (FSH 75 IU: LH 75 IU, 300 IU/day, HUMEGNAN®, Darou Pakhsh Pharmaceutical Mfg. Co., Iran) was initiated. This was continued up to the human chorionic gonadotropin (hCG) trigger. Repeated transvaginal ultrasound was used to monitor ovarian response and guide dose adjustments. The GnRH antagonist, Cetrorelix acetate (250 µg/day, Cetrotide, Merck Serono SA, Switzerland), was given once 2 or more follicles reached ≥ 14 mm in diameter. Cetrotide was ceased upon the attainment of a diameter of ≥ 18 mm in at least 2 follicles, and the final oocyte maturation was triggered using 10,000 IU hCG (Ovitrelle, Merck Serono SA, Switzerland). If no ≥ 14 mm follicles were observed after 8–9 days, the cycle was canceled. Ultrasound-guided OPU was done 36 h after the trigger. The standard ICSI protocol was employed for all participants. Embryos were cryopreserved on day 3 to enhance clinical outcomes, and 2 or 3 cleavage or blastocyst stage embryos were transferred two cycles later, as per established local clinical practice. When only one embryo was available, a single embryo transfer (SET) was executed.

### ART outcomes

In this study, the cumulus-oocyte complexes were stripped of cumulus cells using hyaluronidase enzyme (Sigma®, USA) two hours post the OPU procedure. The oocytes were then evaluated for maturity using a stereo microscope (Olympus SZX7, Tokyo, Japan) and categorized as germinal vesicle (GV), metaphase I (MI), and

metaphase II (MII). Suitable MII oocytes were used for the ICSI procedure, and 16–18 h later, fertilization was evaluated by checking for 2 pronuclei (2 PN) and 2 polar bodies. The study collected data from reproductive outcomes, including parameters related to ovarian response (such as total gonadotrophin, rFSH, and HMG doses, stimulation duration, the number of follicles > 16 mm on the day of triggering, and cycle cancellation rate (Percentage of cycles canceled before OPU per the number of started cycles [49]), the number of retrieved oocytes, the number of MII oocytes, oocyte maturity rate (Percentage of normal MII oocytes per total normal retrieved oocytes [49]), fertilization rate (Percentage of oocytes with 2PN/2 PB, 16–18 h post-insemination per injected MII oocytes [50]), the number of frozen embryos, high-quality embryos (number of grade A and B cleavage embryos according to the ASEBIR (Association for the Study of Reproductive Biology) criteria [51]), canceled embryo transfers (ET) due to the absence of usable embryos, chemical pregnancy rate (percentage of the pregnancies with a positive serum b-hCG test 14 days after ET per the number of ET cycles [52]), and clinical pregnancy rate (percentage of pregnancies showing confirmed clinical markers on ultrasound (like gestational sac and heart rate) per the number of ET cycles [49]). Furthermore, the AFC assessment was conducted pre- and post-intervention.

### Sample size and statistical analysis

The sample size calculation was based on the mean number of MII oocytes. According to similar clinical trials [25, 26, 53, 54], the mean number of MII oocytes in POR patients was considered to be about  $3.2 \pm 2$  in the control group. We anticipated a 50% increase in the mean number of MII oocytes in the intervention group. We determined that a sample size of 50 participants (25 in each arm) was required to detect this difference. To account for a 20% dropout rate, the total sample size was adjusted to 60 participants (30 in each group). This sample size ensures an 80% power to detect a significant difference at the 0.05 significance level. The following formula was applied to calculate the sample size:

$$k = \frac{n_2}{n_1} = 1$$

$$n_1 = \frac{(\sigma_1^2 + \sigma_2^2/K)(z_{1-\alpha/2} + z_{1-\beta})^2}{\Delta^2}$$

$$n_1 = \frac{(2^2 + 2^2/1)(1.96 + 0.84)^2}{1.6^2}$$

$$n_1 = 25$$

$$n_2 = K * n_1 = 25$$

$\Delta = |\mu_2 - \mu_1|$  = absolute difference between two means.

$\sigma_1, \sigma_2$  = variance of mean #1 and #2

$n_1$  = sample size for group #1

$n_2$  = sample size for group #2

$\alpha$  = probability of type I error (usually 0.05)

$\beta$  = probability of type II error (usually 0.2)

$z$  = critical Z value for a given  $\alpha$  or  $\beta$

$k$  = ratio of sample size for group #2 to group #1

Quantitative variables were presented as mean  $\pm$  standard deviation (SD), and qualitative variables were presented as numbers and percentages. Qualitative variables were compared between the AST and placebo groups using Fisher's exact and Pearson's chi-squared tests. The distribution of data was assessed using the Shapiro-Wilk test. To compare continuous variables with a normal distribution between the AST and placebo groups, an independent sample t-test was applied. Non-normally distributed data were analyzed using the Mann-Whitney U test. Pre- and post-intervention markers within each group were compared using Student's paired t-test. Analysis of medication effectiveness between two groups was performed using a repeated-measures analysis of variance (ANOVA) model. Treatment and time effects and also the interaction between time and treatment (time\*group) were included in this model. Logistic regression was employed to assess ART outcomes, with age, AMH, and AFC included as confounding variables, as they are key markers of ovarian response to COS. Statistical significance is denoted by a *P*-value of less than 0.05.

## Results

### Baseline characteristics

Presented in the CONSORT flowchart, the study encompassed the randomization and allocation of 60 patients. Ultimately, 51 participants from this cohort were included in the final analysis (AST group:  $n=26$ , placebo group:  $n=25$ ) (Fig. 1). Importantly, no adverse effects or instances of toxicity were reported by the patients throughout the intervention. At the study's inception, no significant differences emerged in age, BMI, infertility duration, menstrual cycle duration, hormonal profile, AFC, and adherence rates between the two groups (Table 1). Primary infertility was diagnosed in the majority of patients in both groups. Additionally, the predominant stage of embryos transferred in both the AST and placebo groups was the blastocyst stage.

### Serum and FF OS markers and pro-inflammatory cytokines

At baseline, the serum levels of markers displayed no significant differences between the AST and placebo groups. After the intervention, the AST group exhibited a significant increase in serum SOD ( $P=0.013$ ) and TAC ( $P=0.030$ ), along with a significant reduction in serum

**Table 1** Baseline characteristics of the participants

Variables	AST (n = 26)	Placebo (n = 25)	P-value
Age (years)	38.42 ± 1.79	38.32 ± 1.67	0.811
BMI (kg/m <sup>2</sup> )	22.59 ± 1.25	22.46 ± 1.53	0.729
Infertility duration (years)	3.31 ± 1.25	2.88 ± 1.42	0.223
Primary infertility, n (%)	20/26 (76.9%)	17/25 (68.0%)	0.475
Menstrual cycle duration	26.96 ± 3.38	27.44 ± 3.64	0.629
AMH (µg/mL)	0.75 ± 0.16	0.71 ± 0.21	0.368
FSH (mIU/mL)	9.87 ± 1.76	9.95 ± 2.11	0.880
LH (mIU/mL)	4.76 ± 1.17	4.56 ± 1.09	0.523
E2 (pg/mL)	71.63 ± 26.14	68.27 ± 21.89	0.678
P4 (ng/mL)	0.59 ± 0.37	0.53 ± 0.39	0.421
PRL (mIU/L)	200.15 ± 34.50	186.56 ± 28.37	0.132
AFC (n)	4.38 ± 1.41	4.12 ± 1.166	0.365
Adherence rate (%)	98.80 ± 2.01	98.73 ± 2.20	0.945
Blastocyst stage embryo transfer (%)	18/24 (75%)	15/23 (65.2%)	0.464

AST astaxanthin group, BMI body mass index [weight (kg)/height (m<sup>2</sup>)], AMH anti-müllerian hormone, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 estradiol, P4 progesterone, PRL prolactin, AFC antral follicle count, Adherence rate (Number of dosage units dispensed – number of dosage units remained)/ (prescribed number of dosage unit per day × number of days between 2 visits), n number. Table values represent either mean ± SD or number (percentages). Statistical significance is denoted by a P-value of less than 0.05

MDA ( $P=0.005$ ). However, the placebo group showed no significant changes in marker levels after the intervention. Between-group comparisons showed a statistically significant difference in the alterations of serum SOD levels between the AST and placebo groups ( $P=0.027$ ). No significant differences were observed in alterations of serum levels of TAC ( $P=0.246$ ) and MDA ( $P=0.261$ ) between the AST and placebo groups (Table 2). The FF levels of SOD ( $P=0.607$ ), TAC ( $P=0.792$ ), and MDA ( $P=0.887$ ) exhibited no significant differences when comparing the AST group to the placebo group (Table 3).

The results of pro-inflammatory cytokines indicated significant reductions in serum IL-6 ( $P<0.001$ ), IL-8 ( $P=0.001$ ), and VEGF ( $P=0.002$ ) following AST therapy in the AST group. However, no significant changes

in cytokines levels were observed in the placebo group. Between-group comparisons showed statistically significant differences in the alterations of serum IL-6 and IL-8 levels between the groups ( $P<0.001$  and  $P=0.035$ , respectively). No significant difference was observed in the alteration of VEGF ( $P=0.071$ ) between the AST and placebo groups (Table 2). Additionally, in the AST group, FF levels of IL-6 ( $P=0<001$ ), IL-8 ( $P=0.036$ ), and VEGF ( $P=0.006$ ) were significantly lower than in the placebo group (Table 3).

#### FF cfDNA

AST supplementation significantly reduced cfDNA levels, as measured by ALU115 qPCR ( $P<0.001$ ), without

**Table 2** Comparison of pre- and post-intervention serum levels of OS markers and inflammatory cytokines between AST and placebo groups

Variables	AST (n = 26)			Placebo (n = 25)			P-value between groups
	Pre-intervention serum levels	Post-intervention serum levels	Paired P-value	Pre-intervention serum levels	Post-intervention serum levels	Paired P-value	
SOD (U/ml)	14.97 ± 2.26	16.26 ± 2.22	0.013*	15.28 ± 2.01	14.59 ± 3.59	0.351	0.027*
TAC (µmol/L)	892.50 ± 81.77	910.05 ± 92.56	0.030*	918.73 ± 127.35	889.06 ± 203.20	0.468	0.246
MDA (µmol/L)	16.82 ± 1.22	16.19 ± 1.27	0.005*	16.74 ± 1.44	16.43 ± 1.64	0.135	0.261
IL-6 (pg/ml)	1.74 ± 0.33	1.25 ± 0.32	0.000*	1.61 ± 0.33	1.67 ± 0.30	0.098	0.000*
IL-8 (pg/ml)	14.62 ± 1.87	13.38 ± 1.65	0.001*	14.58 ± 2.22	14.28 ± 2.55	0.323	0.035*
VEGF (pg/ml)	13.20 ± 2.96	12.37 ± 2.87	0.002*	12.71 ± 3.19	12.43 ± 3.20	0.123	0.071

AST Astaxanthin group, SOD superoxide dismutase, TAC total antioxidant capacity, MDA malondialdehyde, IL-6 interleukin 6, IL-8 interleukin 8, VEGF vascular endothelial growth factor. Table values represent mean ± SD. Statistical significance is denoted by a P-value of less than 0.05 (\* $P<0.05$ )

**Table 3** Comparison of FF levels of OS markers, inflammatory cytokines, and cfDNA between AST and placebo groups

Variables	AST (n = 26), FF levels	Placebo (n = 25), FF levels	P-value
SOD (U/ml)	14.49 ± 2.12	14.83 ± 2.60	0.607
TAC (μmol/L)	816.18 ± 126.06	835.71 ± 149.95	0.792
MDA (μmol/L)	12.94 ± 1.16	13.32 ± 2.05	0.887
IL-6 (pg/ml)	2.05 ± 0.60	2.98 ± 1.02	0.000*
IL-8 (pg/ml)	24.52 ± 3.68	28.66 ± 8.74	0.036*
VEGF (pg/ml)	11.04 ± 2.06	13.16 ± 3.02	0.006*
CfDNA level (ALU115) (ng/μl)	0.39 ± 0.12	0.60 ± 0.17	0.000*
ALU247 (ng/μl)	0.18 ± 0.07	0.21 ± 0.07	0.133
CfDNA integrity (ALU 247/ ALU 115)	0.48 ± 0.14	0.38 ± 0.13	0.014*

AST astaxanthin group, SOD superoxide dismutase, TAC total antioxidant capacity, MDA malondialdehyde, IL-6 interleukin 6, IL-8 interleukin 8, VEGF vascular endothelial growth factor, cfDNA Cell-free DNA, FF follicular fluid. Table values represent mean ± SD. Statistical significance is denoted by a P-value of less than 0.05 (\*P < 0.05)

affecting ALU247 levels ( $P=0.133$ ) compared to the placebo group. Furthermore, cfDNA integrity significantly increased in the AST group compared to the placebo group ( $P=0.014$ ). The mean Q247/Q115 ratio in FF samples was  $0.48 \pm 0.14$  in the AST group and  $0.38 \pm 0.13$  in the placebo group, suggesting that the analyzed cfDNA predominantly originates from cellular apoptosis.

#### Ovarian stimulation parameters and ART outcomes

The AST group showed a significant increase in the number of retrieved oocytes ( $P=0.003$ ), MII oocytes

( $P=0.004$ ), frozen embryos ( $P=0.037$ ), and high-quality embryos ( $P=0.014$ ) compared to the placebo group. Notably, other factors such as total gonadotrophin ( $P=0.207$ ), rFSH ( $P=0.149$ ), and HMG doses ( $P=0.299$ ), stimulation duration ( $P=0.149$ ), the number of follicles > 16 mm ( $P=0.186$ ), oocyte maturity rate ( $P=0.089$ ), fertilization rate ( $P=0.973$ ), canceled ET ( $P=0.682$ ), chemical pregnancy rate ( $P=0.995$ ), and clinical pregnancy rate ( $P=0.695$ ), showed no significant changes between the AST and placebo groups (Table 4). Also, The cycle cancellation rate showed no

**Table 4** Comparison of ART cycle stimulation parameters, embryology, and clinical reproductive outcomes between AST and placebo groups

Variables	AST (n = 26)	Placebo (n = 25)	P-value <sup>#</sup>
Total gonadotrophin doses (IU)	5648.08 ± 623.816	5862.00 ± 653.00	0.207
rFSH doses (IU)	2423.08 ± 232.155	2520.00 ± 243.02	0.149
HMG dose (IU)	3225.00 ± 453.486	3342.00 ± 427.61	0.299
Stimulation duration (days)	10.77 ± 1.03	11.20 ± 1.08	0.149
Number of follicles >16mm	4.42 ± 1.33	3.96 ± 1.13	0.186
Retrieved oocytes (n)	4.38 ± 1.35	3.36 ± 1.03	0.003*
GV (n)	0.73 ± 0.60	0.88 ± 0.60	0.188
MI (n)	0.27 ± 0.45	0.32 ± 0.47	0.723
MII (n)	3.38 ± 1.44	2.16 ± 0.89	0.004*
Oocyte maturity rate (MII %)	75.64 ± 17.03	66.00 ± 22.02	0.089
Fertilization rate (%)	89.74 ± 15.33	90.33 ± 16.25	0.973
Frozen embryos (n)	2.73 ± 1.61	1.80 ± 0.86	0.037*
High-quality embryos (n)	2.62 ± 1.41	1.64 ± 0.75	0.014*
Transferred embryos (n)	1.73 ± 0.66	1.68 ± 0.74	0.776
Canceled ET, n (%)	2/26 (7.7%)	2/25 (8.0%)	0.682
Chemical pregnancy rate, n (%)	9/24 (37.5%)	8/23 (34.8%)	0.995
Clinical pregnancy rate, n (%)	5/24 (20.8%)	4/23 (17.4%)	0.695

AST Astaxanthin group, rFSH recombinant follicle-stimulating hormone, HMG human menopausal gonadotropin, GV germinal vesicle, MI metaphase I, MII metaphase II, ET embryo transfer, n Number. Table values represent either mean ± SD or number (percentages) <sup>#</sup>Logistic regression adjusted for age, AMH, and AFC as confounding variables. Statistical significance is denoted by a P-value of less than 0.05 (\*P < 0.05)



significant difference between the AST group (3/29, 10.3%) and the placebo group (4/29, 13.8%) ( $P=1.000$ ). Furthermore, the pre- and post-intervention changes in AFC did not significantly differ between the AST ( $4.38 \pm 1.41$  vs.  $4.42 \pm 1.33$ ;  $P=0.788$ ) and placebo groups ( $4.12 \pm 1.16$  vs.  $4.00 \pm 1.15$ ;  $P=0.083$ ) ( $P$ -value between groups = 0.321).

## Discussion

The pathophysiology of POR primarily stems from the limited number of follicles that respond to COS [55]. This leads to fewer retrieved oocytes, lower chances of conception, and a higher risk of cycle cancellation [56]. OS, inflammation, and apoptosis are key contributors to this condition [8–11]. OS, in particular, accelerates ovarian aging and damages critical macromolecules, impairing oocyte quality, embryo development, and implantation [57]. Pro-inflammatory cytokines disrupt the function of GCs, which are crucial for oocyte maturation, further exacerbating POR through impaired FSH signaling [9]. Elevated levels of ROS also promote apoptosis in oocytes and GCs, worsening ovarian function [14]. While various stimulation protocols and adjuvant treatments have been explored, significant improvements in ART outcomes for POR patients remain limited [56]. Astaxanthin, with its potent antioxidant, anti-inflammatory, and anti-apoptotic properties, may help improve POR [29]. To explore this, we conducted a randomized, triple-blind, placebo-controlled trial with POR patients, assessing astaxanthin's role as a COS adjuvant on ovarian response, ART outcomes, and markers of OS, inflammation, and apoptosis.

Antioxidant supplementation holds considerable promise in mitigating the detrimental effects of OS on oocyte and embryo quality in patients with POR [8, 58–60]. In this trial, AST therapy demonstrated remarkable advancements in oocyte quantity and maturity, the number of frozen embryos, and high-quality embryos. Our study results suggest that AST has the potential to enhance the FF quality, a critical factor in oocyte development. We hypothesized that mitigating OS, reducing inflammation, and inhibiting apoptosis, all linked to POR, could achieve this improvement. Consequently, these effects likely result in the production of higher-quality oocytes, subsequently leading to the development of high-quality embryos and an overall improvement in other ART outcomes. On the other hand, the fertilization rate between the two groups was similar. It's important to note that even when excluding male factor patients, sperm quality can still influence the fertilization process. No significant differences were observed in ovarian response parameters, oocyte maturity rate, canceled ET,

pregnancy outcomes, and AFC. Further research with a larger sample size is warranted to explore the impact of varying AST dosages and treatment durations, which could potentially yield different outcomes regarding astaxanthin's effectiveness. The findings from this study are consistent with our prior clinical trials involving PCOS and endometriosis patients [37, 41]. Similar results were seen with CoQ10 therapy in a trial for POR patients [26].

In our trial, serum levels of all OS markers were improved in the AST group. There was a statistically significant difference in the alterations of serum SOD levels between the groups, but not in TAC and MDA levels. However, FF levels of OS markers did not change between the two groups. Results align with earlier RCTs, showing AST supplementation's positive impact on OS in overweight/obese individuals [61, 62]. Our previous studies demonstrated increased TAC levels in PCOS patients' FF, while SOD and MDA showed no significant changes following AST supplementation [37]. Likewise, in endometriosis patients, AST elevated serum SOD and TAC levels and reduced MDA, but no significant changes in OS markers were observed in the FF [41].

Notably, AST was found to significantly decrease IL-6, IL-8, and VEGF levels both in the serum and FF of the AST group. There were statistically significant differences in the alterations of serum IL-6 and IL-8 levels between the groups, but not in VEGF levels. Reports indicate that IL-6 reduces follicular aromatase activity, leading to lower E2 levels and negatively affecting fertility and fertilizing capacity [8]. Additionally, IL-8 attracts and activates leukocytes and macrophages, intensifying OS by promoting ROS production [63]. Schafer et al.'s findings support a positive association between OS and VEGF gene expression [64]. Our study concurs with earlier research, highlighting AST's ability to reduce pro-inflammatory cytokine levels in the serum and FF of endometriosis patients [41]. Meanwhile, AST has demonstrated the ability to regulate essential pro-inflammatory factors, including IL-1 $\beta$ , IL-6, IL-8, VEGF, and TNF- $\alpha$  [65, 66]. In 2016, Nuñez-Calonge et al. reported increased OS markers and pro-inflammatory cytokines (IL-6, IL-8, VEGF) in FF of low ovarian response patients, along with reduced antioxidant enzyme activity [8]. Taghavi et al. also observed elevated IL-6 and IL-8 levels in POR women compared to normal responders [9]. However, our findings highlight the potential of AST in promoting antioxidant balance and combating OS and inflammation associated with POR.

In the current study, the observed significant reduction in cfDNA levels (ALU115) and the significant increase in cfDNA integrity, accompanied by an unchanged ALU247 level (a marker of necrosis) following AST therapy, suggest that AST's anti-apoptotic effects may contribute to

these changes. OS-induced apoptosis in follicles and GCs can lead to the release of cfDNA into the FF [46, 67]. Also, apoptosis-induced cell debris continues to affect the ovarian microenvironment by increasing cfDNA levels, which stimulates intracellular ROS production and intensifies apoptosis [68]. The association between cfDNA levels in FF and ovarian reserve is of notable significance. Moreover, increased cfDNA in FF is linked to POR, and reduced oocyte and embryo quantity/quality, leading to poor ART outcomes [46, 68]. In a 2019 study by Nagireddy et al., serum cfDNA levels in low ovarian responders correlated positively with FSH levels and negatively with AFC and AMH levels [69]. In our 2021 experiment, AST reduced OS and showed a modest decrease in the rate of apoptosis in the GCs of a PCOS mouse model, and activated the PI3K/AKT pathway [70]. Besides, in a 2023 clinical trial, AST suppressed GCs apoptosis triggered by endoplasmic reticulum stress in PCOS patients [37]. Indeed, the evidence consistently confirms AST's capacity to inhibit apoptosis induced by OS [71]. This aligns with the recent trial in POR patients, where AST demonstrated the ability to decrease cfDNA levels in FF, possibly by countering OS-induced apoptosis through its antioxidant and anti-apoptotic properties. However, additional research is needed to assess cfDNA levels in serum following AST therapy.

Given the limited number of clinical studies investigating the effects of AST on female infertility and reproductive outcomes [40], our study is innovative, as no clinical trials have specifically explored AST's effects on POR patients. To the best of our knowledge, this marks the first randomized, triple-blind, placebo-controlled clinical trial investigating the impact of AST supplementation on OS markers, pro-inflammatory cytokines, cfDNA, and ART outcomes in POR patients. Our research's strength lies in assessing a homogeneous (Group 4, according to the POSEIDON stratification, representing the poorest prognosis category), nationwide group of POR patients who underwent consistent treatment procedures. In addition, we chose cfDNA as an apoptosis biomarker in FF due to its strong link to cellular death. Moreover, cfDNA offers several advantages over other apoptotic markers, including its stability, ease of quantification, and potential as a non-invasive biomarker. Furthermore, FF cfDNA may serve as a novel indicator of follicular microenvironment quality [46]. It is pertinent to highlight that our study had some limitations. To achieve a more robust analysis of pregnancy outcomes, a larger sample size is imperative. Unfortunately, we were unable to evaluate the LBR, a crucial ART success indicator, due to time constraints. Additionally, the study did not assess serum cfDNA levels and focused on frozen ICSI cycles.

## Conclusion

In conclusion, AST demonstrates promise as an adjuvant therapy in COS for patients with POR. Our findings suggest that AST supplementation may improve ART outcomes, including an increased number of retrieved oocytes, MII oocytes, frozen embryos, and high-quality embryos. These improvements are likely mediated through the mitigation of OS (evidenced by elevated SOD and TAC levels and reduced MDA), the reduction of inflammatory markers (IL-6, IL-8, VEGF), and the suppression of apoptotic activity (as indicated by decreased cfDNA levels).

## Abbreviations

POR	Poor ovarian response
ART	Assisted reproductive technology
COS	Controlled ovarian stimulation
OS	Oxidative stress
FSH	Follicle-stimulating hormone
FSHR	Follicle-stimulating hormone receptor
GCs	Granulosa cells
ROS	Reactive oxygen species
cfDNA	Cell-free DNA
FF	Follicular fluid
LBR	Live birth rates
AST	Astaxanthin
CoQ10	Coenzyme Q10
Nrf2/HO-1	Nuclear factor erythroid 2-related factor 2/ heme oxygenase-1
NF-κB	Nuclear factor kappa B
MAPK	Mitogen-activated protein kinase family
ERK	Extracellular signal-regulated kinase
PI3K/Akt	Phosphoinositide 3-kinase/protein kinase B
AMH	Anti-müllerian hormone
AFC	Antral follicle count
POSEIDON	Patient-Oriented Strategies Encompassing Individualize Oocyte Number) stratification
PCOS	Polycystic ovary syndrome
CONSORT	Consolidated Standards of Reporting Trials
ICSI	Intracytoplasmic sperm injection
GnRH	Gonadotropin-releasing hormone
OPU	Ovum pick-up
SOD	Superoxide dismutase
TAC	Total antioxidant capacity
MDA	Malondialdehyde
IL-6	Interleukin-6
IL-8	Interleukin-8
VEGF	Vascular endothelial growth factor
ELISA	Enzyme-linked immunosorbent assay
rFSH	Recombinant FSH
HMG	Human menopausal gonadotrophin
hCG	Human chorionic gonadotropin
SET	Single embryo transfer
GV	Germinal vesicle
MI	Metaphase I
MII	Metaphase II
2 PN	2 pronuclei
ASEBIR	Association for the Study of Reproductive Biology
ET	Embryo transfers
SD	Standard deviation
ANOVA	Analysis of variance

## Acknowledgements

The authors acknowledge the financial support provided by the Tehran University of Medical Sciences, Tehran, Iran, under grant number 1401-4-410-64220, for this study. Also, we are grateful to all the participants for their invaluable time and commitment.

### Authors' contributions

Anahid Shafie: Conducted investigations, contributed to the methodology and project administration, and drafted the initial manuscript. Ashraf Aleyasin: Contributed to the project administration and supervision, provided expert guidance and feedback, and assisted in the review and editing of the manuscript. Mojtaba Saffari: Conducted investigations, prepared visualizations, and provided critical feedback during the manuscript review process. Mojtaba Saedi: Conducted investigations, prepared visualizations, and contributed to the manuscript review process. Sahar Rostami: Conducted investigations, prepared visualizations, and contributed to the manuscript review process. Saeede Rezayi: Performed formal data analysis, prepared visualizations, and contributed to the manuscript review process. Seyed Danial Mohammadi: Conducted formal data analysis, contributed to manuscript review, and Addressed reviewers' revisions. Fardin Amidi: Conceptualized and designed the study, oversaw the methodology and project administration, supervised the research, and provided critical feedback and guidance throughout the project and the manuscript review process. All authors contributed to the final approval of the version to be published and agreed to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### Funding

This study was financially supported by the Tehran University of Medical Sciences, Tehran, Iran (grant number: 1401-4-410-64220). The funding source was not involved in the study design, data collection, analysis, or interpretation.

### Data availability

No datasets were generated or analysed during the current study.

### Declarations

#### Ethics approval and consent to participate

This study was performed in accordance with the principles of the Declaration of Helsinki. The trial received approval from the Deputy of the Research and Ethics Committee of TUMS (approval date: 2023 January 01; code: IR.TUMS.MEDICINE.REC.1401.636). Before participating in the study, all participants provided written informed consent.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare no competing interests.

#### Author details

<sup>1</sup>Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Poorsina Ave, P.O. Box: 1461884513, Tehran, Iran. <sup>2</sup>Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. <sup>3</sup>Department of Obstetrics and Gynecology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. <sup>4</sup>Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. <sup>5</sup>Department of Obstetrics and Gynecology, Yas Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Received: 10 August 2024 Accepted: 15 October 2024

Published online: 31 October 2024

### References

- Giannelou P, Simopoulou M, Grigoriadis S, Makrakis E, Kontogeorgi A, Pantou A, et al. The conundrum of poor ovarian response: from diagnosis to treatment. *Diagnostics* (Basel). 2020;10(9):687.
- Veneti CA, Kolibianakis EM, Tarlatzis TB, Tarlatzis BC. Evidence-based management of poor ovarian response. *Ann NY Acad Sci*. 2010;1205(1):199–206.
- Drakopoulos P, Blockeel C, Stoop D, Camus M, De Vos M, Tournaye H, Polyzos NP. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? *Hum Reprod*. 2016;31(2):370–6.
- Law YJ, Zhang N, Kolibianakis EM, Costello MF, Keller E, Chambers GM, Veneti CA. Is there an optimal number of oocytes retrieved at which live birth rates or cumulative live birth rates per aspiration are maximized after ART? A systematic review. *Reprod Biomed Online*. 2021;42(1):83–104.
- Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. Definition EPOR. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. *Hum Reprod*. 2011;26(7):1616–24.
- Alviggi C, Andersen C, Buehler K, Conforti A, De Placido G, Esteves S, et al. Poseidon Group (patient-Oriented strategies encompassing Individualized oocyte number). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. *Fertil Steril*. 2016;105(6):1452–3.
- Annalisa R, Dominic S, Nikolaos PP. Diminished ovarian reserve and poor ovarian response: diagnostic and therapeutic management. *Front Physiol*. 2022;13:827678.
- Nunez-Calonge R, Cortes S, Gutierrez Gonzalez LM, Kireev R, Vara E, Ortega L, et al. Oxidative stress in follicular fluid of young women with low response compared with fertile oocyte donors. *Reprod Biomed Online*. 2016;32(4):446–56.
- Taghavi SA, Ashrafi M, Mehdizadeh M, Karimian L, Joghataie MT, Aflatoonian R. Toll-like receptors expression in follicular cells of patients with poor ovarian response. *Int J Fertil Steril*. 2014;8(2):183–92.
- Luddi A, Capaldo A, Focarelli R, Gori M, Morgante G, Piomboni P, De Leo V. Antioxidants reduce oxidative stress in follicular fluid of aged women undergoing IVF. *Reprod Biol Endocrinol*. 2016;14(1):57.
- Regan SLP, Knight PG, Yovich JL, Leung Y, Arfuso F, Dharmarajan A. Granulosa Cell apoptosis in the ovarian follicle-A changing view. *Front Endocrinol* (Lausanne). 2018;9:61.
- Kaltsas A, Zikopoulos A, Moustakli E, Zachariou A, Tsirka G, Tsiampali C, et al. The Silent threat to women's fertility: uncovering the devastating effects of oxidative stress. *Antioxid* (Basel). 2023;12(8):1490.
- Adashi EY. Endocrinology of the ovary. *Hum Reprod*. 1994;9(5):815–27.
- Redza-Dutoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. *Biochim Biophys Acta Mol Cell Res*. 2016;1863(12):2977–92.
- Yan F, Zhao Q, Li Y, Zheng Z, Kong X, Shu C, et al. The role of oxidative stress in ovarian aging: a review. *J Ovarian Res*. 2022;15(1):100.
- Regan S, Knight P, Yovich J, Leung Y, Arfuso F, Dharmarajan A. Granulosa cell apoptosis in the ovarian follicle-a changing view. *Front Endocrinol*. 2018;9(2018):61.
- Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. *Crit Rev Clin Lab Sci*. 2014;51(4):200–31.
- Scalici E, Traver S, Molinari N, Mullet T, Monforte M, Vintejoux E, Hamamah S. Cell-free DNA in human follicular fluid as a biomarker of embryo quality. *Hum Reprod*. 2014;29(12):2661–9.
- Traver S, Assou S, Scalici E, Haouzi D, Al-Edani T, Belloc S, Hamamah S. Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy. *Hum Reprod Update*. 2014;20(6):905–23.
- Baka S, Malamitsi-Puchner A. Novel follicular fluid factors influencing oocyte developmental potential in IVF: a review. *Reprod Biomed Online*. 2006;12(4):500–6.
- Ficicioglu C, Cenksoy PO, Yildirim G, Kaspar C. Which cut-off value of serum anti-Müllerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation and in vitro fertilization success? A prospective data analysis. *Gynecol Endocrinol*. 2014;30(5):372–6.
- Seifer DB, Gardiner AC, Ferreira KA, Peluso JJ. Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization. *Fertil Steril*. 1996;66(4):593–8.
- Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian response: a systematic review and meta-analysis. *J Hum Reprod Sci*. 2016;9(2):70–81.
- Blumenfeld Z. What is the best regimen for ovarian stimulation of poor responders in ART/IVF? *Front Endocrinol* (Lausanne). 2020;11:192.
- Gong Y, Luo S, Fan P, Jin S, Zhu H, Deng T, et al. Growth hormone alleviates oxidative stress and improves oocyte quality in Chinese women with polycystic ovary syndrome: a randomized controlled trial. *Sci Rep*. 2020;10(1):18769.

26. Xu Y, Nisenblat V, Lu C, Li R, Qiao J, Zhen X, Wang S. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. *Reprod Biol Endocrinol*. 2018;16(1):29.
27. Wang J, Liu B, Wen J, Qu B. The role of dehydroepiandrosterone in improving in vitro fertilization outcome in patients with DOR/POR: a systematic review and Meta-analysis. *Comb Chem High Throughput Screen*. 2023;26(5):916–27.
28. Kohandel Z, Farkhondeh T, Aschner M, Samarghandian S. Nrf2 a molecular therapeutic target for Astaxanthin. *Biomed Pharmacother*. 2021;137:111374.
29. Ambati RR, Phang SM, Ravi S, Aswathanarayana RG. Astaxanthin: sources, extraction, stability, biological activities and its commercial applications—a review. *Mar Drugs*. 2014;12(1):128–52.
30. Suyono EA, Pradani L, Mu'avatun U, Habiba RN, Rohma EF. Combination of blue, red, white, and ultraviolet lights for increasing carotenoids and biomass of microalga *Haematococcus pluvialis*. *Procedia Environ Sci*. 2015;28:399–405.
31. Howden R. Nrf2 and cardiovascular defense. *Oxid Med Cell Longev*. 2013;2013(1):104308.
32. Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea F. Astaxanthin: a review of its chemistry and applications. *Crit Rev Food Sci Nutr*. 2006;46(2):185–96.
33. Kohandel Z, Farkhondeh T, Aschner M, Pourbagher-Shahri AM, Samarghandian S. Anti-inflammatory action of astaxanthin and its use in the treatment of various diseases. *Biomed Pharmacother*. 2022;145: 112179.
34. Zhang H, Tsao R. Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects. *Curr Opin Food Sci*. 2016;8:33–42.
35. Kim SH, Kim H. Astaxanthin modulation of signaling pathways that regulate autophagy. *Mar Drugs*. 2019;17(10): 546.
36. Yan T, Zhao Y, Zhang X, Lin X. Astaxanthin inhibits acetaldehyde-induced cytotoxicity in SH-SY5Y cells by modulating Akt/CREB and p38MAPK/ERK signaling pathways. *Mar Drugs*. 2016;14(3): 56.
37. Jabarpour M, Aleyasin A, Nashtaei MS, Lotfi S, Amidi F. Astaxanthin treatment ameliorates ER stress in polycystic ovary syndrome patients: a randomized clinical trial. *Sci Rep*. 2023;13(1):3376.
38. Brendler T, Williamson EM. Astaxanthin: how much is too much? A safety review. *Phytother Res*. 2019;33(12):3090–111.
39. Williamson EM, Liu X, Izzo AA. Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals. *Br J Pharmacol*. 2020;177(6):1227–40.
40. Maleki-Hajiagha A, Shafie A, Maajani K, Amidi F. Effect of astaxanthin supplementation on female fertility and reproductive outcomes: a systematic review and meta-analysis of clinical and animal studies. *J Ovarian Res*. 2024;17(1):163.
41. Rostami S, Alyasin A, Saedi M, Nekoonam S, Khodarahmian M, Moeini A, Amidi F. Astaxanthin ameliorates inflammation, oxidative stress, and reproductive outcomes in endometriosis patients undergoing assisted reproduction: a randomized, triple-blind placebo-controlled clinical trial. *Front Endocrinol (Lausanne)*. 2023;14:1144323.
42. Gharaei R, Alyasin A, Mahdavezhad F, Samadian E, Ashrafnezhad Z, Amidi F. Randomized controlled trial of astaxanthin impacts on antioxidant status and assisted reproductive technology outcomes in women with polycystic ovarian syndrome. *J Assist Reprod Genet*. 2022;39(4):995–1008.
43. Fereidouni F, Kashani L, Amidi F, Khodarahmian M, Zhaeentan S, Ardehiani NA, Rastegar T. Astaxanthin treatment decreases pro-inflammatory cytokines and improves reproductive outcomes in patients with polycystic ovary syndrome undergoing assisted reproductive technology: a randomized clinical trial. *Inflammopharmacology*. 2024;32(4):2337–47.
44. Jabarpour M, Aleyasin A, Nashtaei MS, Khodarahmian M, Lotfi S, Amidi F. The modulating effects of astaxanthin on apoptosis in women with polycystic ovarian syndrome: a randomized clinical trial. *Avicenna J Phytomed*. 2024;14(1):64–77.
45. Lam WY, Fresco P. Medication adherence measures: an overview. *Biomed Res Int*. 2015;2015:217047.
46. Traver S, Scalici E, Mullet T, Molinari N, Vincens C, Anahory T, Hamamah S. Cell-free DNA in human follicular microenvironment: New Prognostic Biomarker to predict in vitro fertilization outcomes. *PLoS ONE*. 2015;10(8): e0136172.
47. Debbbarh H, Jamil M, Jelloul H, Zakaria A, Louanjili N, Cadi R. Assessment of cell-free DNA and apoptosis in an oocyte microenvironment: promising biomarkers to predict intracytoplasmic sperm injection outcomes. *Zygote*. 2023;31(3):296–302.
48. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, Hoon DS. Increased integrity of free circulating DNA in sera of patients with colorectal or perianapillary cancer: direct quantitative PCR for ALU repeats. *Clin Chem*. 2006;52(6):1062–9.
49. Group ECPW, Vlaisavljevic V, Apter S, Capalbo A, D'Angelo A, Gianaroli L, et al. The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. *Hum Reprod Open*. 2021;2021(3):hoab022.
50. of Embryology ESIG. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. *Reprod Biomed Online*. 2017;35(5):494–510.
51. Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. *Hum Reprod*. 2011;26(6):1270–83.
52. Bassiouny YA, Dakhly DMR, Bayoumi YA, Hashish NM. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. *Fertil Steril*. 2016;105(3):697–702.
53. Safdarian L, Aghahosseini M, Alyasin A, Samaei-Nouroozi A, Rashidi S, Shabani-Nashtaei M, et al. Growth hormone (GH) improvement of ovarian responses and pregnancy outcome in poor ovarian responders: a randomized study. *Asian Pac J Cancer Prev*. 2019;20(7):2033.
54. Mohammadi S, Eini F, Bazarganipour F, Taghavi SA, Kutenae MA. The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial. *Reprod Biol Endocrinol*. 2021;19:1–7.
55. Esteves SC, Roque M, Bedoschi GM, Conforti A, Humaidan P, Alviggi C. Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON criteria—the why. *Front Endocrinol (Lausanne)*. 2018;9:461.
56. Abu-Musa A, Haahr T, Humaidan P. Novel physiology and definition of poor ovarian response; clinical recommendations. *Int J Mol Sci*. 2020;21(6): 2110.
57. Kaltsas A, Zikopoulos A, Moustakli E, Zachariou A, Tsiara G, Tsiampali C, et al. The Silent threat to women's fertility: uncovering the devastating effects of oxidative stress. *Antioxidants*. 2023;12(8): 1490.
58. Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on female reproduction: a review. *Reprod Biol Endocrinol*. 2012;10: 49.
59. Rasool S, Shah D. Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel's back. *Fertil Res Pract*. 2017;3(1):15.
60. Jiménez Tuñón JM, Trilles PP, Molina MG, Duvison MH, Pastor BM, Martín PS, et al. A double-blind, randomized prospective study to evaluate the efficacy of previous therapy with melatonin, myo-inositol, folic acid, and selenium in improving the results of an assisted reproductive treatment. *Clin Med Insights Ther*. 2017;9:1179559X17742902.
61. Choi HD, Youn YK, Shin WG. Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects. *Plant Foods Hum Nutr*. 2011;66:363–9.
62. Choi HD, Kim JH, Chang MJ, Kyu-Youn Y, Shin WG. Effects of astaxanthin on oxidative stress in overweight and obese adults. *Phytother Res*. 2011;25(12):1813–8.
63. Akhter N, Wilson A, Thomas R, Al-Rashed F, Kochumon S, Al-Roub A, et al. ROS/TNF-alpha crosstalk triggers the expression of IL-8 and MCP-1 in human monocytic THP-1 cells via the NF-kappaB and ERK1/2 mediated signaling. *Int J Mol Sci*. 2021;22(19):10519.
64. Schäfer G, Cramer T, Suske G, Kemmer W, Wiedenmann B, Höcker M. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. *J Biol Chem*. 2003;278(10):8190–8.
65. Talukdar J, Bhadra B, Dattaroy T, Nagle V, Dasgupta S. Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19. *Biomed Pharmacother*. 2020;132: 110886.
66. Chang MX, Xiong F. Astaxanthin and its effects in inflammatory responses and inflammation-Associated diseases: recent advances and future directions. *Molecules*. 2020;25(22): 5342.



67. Fan Y, Chang Y, Wei L, Chen J, Li J, Goldsmith S, et al. Apoptosis of mural granulosa cells is increased in women with diminished ovarian reserve. *J Assist Reprod Genet.* 2019;36:1225–35.
68. Guan Y, Zhang W, Wang X, Cai P, Jia Q, Zhao W. Cell-free DNA induced apoptosis of granulosa cells by oxidative stress. *Clin Chim Acta.* 2017;473:213–7.
69. Nagireddy S, Katneni L. Cell free DNA is an ideal ovarian reserve marker for low ovarian response for stimulation. *Fertil Steril.* 2019;112(3):e188.
70. Ebrahimi F, Rostami S, Nekoonam S, Rashidi Z, Sobhani A, Amidi F. The Effect of Astaxanthin and Metformin on oxidative stress in Granulosa cells of BALB C mouse model of polycystic ovary syndrome. *Reprod Sci.* 2021;28(10):2807–15.
71. Li Z, Dong X, Liu H, Chen X, Shi H, Fan Y, et al. Astaxanthin protects ARPE-19 cells from oxidative stress via upregulation of Nrf2-regulated phase II enzymes through activation of PI3K/Akt. *Mol vis.* 2013;19:1656.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.